Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 weeks ago Myeloma

New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma

Multiple Myeloma

#BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART

Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving long-term remission and extended survival remains difficult. The recent introduction of CD27-armored BCMA CAR-T—CBG-002—by a Chinese medical team brings new hope for RRMM patients. Based on preclinical data, this therapy shows promising anti-myeloma activity, with Phase I clinical trial results further validating its efficacy and safety.

Research Highlights

CBG-002 is an innovative therapy that enhances traditional BCMA CAR-T by adding a CD27 costimulatory domain. The inclusion of CD27 improves CAR-T cell persistence and activity, contributing to stronger anti-cancer effects. Recently published Phase I research in Cancer Immunology Research indicates that this CD27-armored BCMA CAR-T therapy is not only well-tolerated but also shows notable efficacy in RRMM patients.

The study enrolled 11 RRMM patients, all of whom had undergone three or more prior treatments, with a median age of 54. The results showed that 81.8% of patients experienced only mild cytokine release syndrome (CRS) and no severe neurotoxicity. Even at a low dosage level (1-3×10^6 CAR-T cells/kg), CBG-002 achieved a high overall response rate (ORR) of 81.8%, with 45.5% of patients reaching stringent complete remission.

Future Outlook

The Phase I study of CBG-002 not only confirmed its efficacy but also demonstrated advantages in production time and cost. Compared to current products on the market, CBG-002 has a shortened production cycle of just 10 days, making it a timely and affordable treatment option for more patients. Amid global progress in CAR-T cell therapies, the innovation by this Chinese medical team positions it as a significant force in advancing cancer research worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CancerResearch #Immunotherapy #ChinaBiotech #Oncology

1 month ago CAR-T

Why Are More and More International Patients Coming to China for CAR-T Cell Therapy?

CARTtherapy

#CARTtherapy #InternationalPatient #CART #Multiplemyeloma #lymphoma #leukemia

In recent years, CAR-T cell therapy, as an innovative cancer treatment, has rapidly gained widespread attention globally. China, as a leading country in the CAR-T treatment field, has attracted an increasing number of patients from Europe and Asia due to its advanced technology, high-quality medical resources, and relatively lower treatment costs. So, why are more international patients choosing to come to China for CAR-T treatment? Here are some key reasons worth noting:

### 1. Advanced CAR-T Treatment Technology

Over the past decade, China has made tremendous strides in medical research, particularly in the field of cancer immunotherapy. Not only has China successfully developed various CAR-T therapies, but it has also built a comprehensive treatment protocol and safety monitoring system to ensure efficient and safe treatment for patients. Additionally, China has accumulated extensive experience in managing treatment-related side effects, such as CRS (Cytokine Release Syndrome) and neurotoxicity.

Currently, more than 50% of the world’s clinical trials for CAR-T therapy are conducted in China. Of the 11 CAR-T products already on the global market, five are from China. These include products for multiple myeloma (BCMA CAR-T), diffuse large B-cell lymphoma (CD19 CAR-T), and leukemia. Compared to similar products in the U.S. for multiple myeloma, China’s CAR-T products are not only fully humanized but also boast the highest complete remission rates among all available products, reaching 82.4%. The CR data for China’s lymphoma and leukemia CAR-T products are also impressive, at 77.6% and 82.1%, respectively.

### 2. International Certification and Clinical Trial Opportunities

Several hospitals and research institutions in China have gained international recognition for their CAR-T therapies. Patients can choose between commercial CAR-T treatments or participate in clinical trials. For some CAR-T treatments that have not yet been approved or are hard to access in Europe or Asia, patients can receive these cutting-edge therapies in China earlier.

Just a few days ago, Chinese scholars’ research on universal CAR-T cell therapy was featured on the cover of Nature. Various other studies on Chinese CAR-T therapies are frequently published in major medical journals. For example, a Chinese medical team published a study on dual-target CAR-T in JAMA Oncology, showing a 100% stringent complete remission (sCR) rate in high-risk multiple myeloma patients. Additionally, a research team from Zhejiang, China, published clinical data in Cell Discovery, highlighting the breakthrough of the fourth-generation anti-CD19 CAR-T cell therapy in treating relapsed/refractory large B-cell lymphoma with exceptional anti-tumor capabilities.

### 3. Relatively Low Treatment Costs

Compared to the million-dollar treatment costs in Western countries, CAR-T treatment in China is relatively affordable, often costing just 1/5 to 1/7 of the price in the U.S. For instance, the cheapest CAR-T product for multiple myeloma in the U.S. costs $420,000, and when including hospitalization and other expenses, the total cost can reach around $700,000. In contrast, similar Chinese products, with equal or even better effectiveness, cost only $160,000, and hospitalization and other fees are much lower, often under $10,000. Some treatment options are available for just a few tens of thousands of dollars, and in certain cases, treatment is even completely free.

Patients from Europe and Asia can receive world-class CAR-T therapy in China at a much lower cost, providing an affordable option for those who find the high costs of treatment elsewhere prohibitive. Moreover, a range of one-stop medical services, including hospital visits, translation assistance, transportation, accommodation, and even family care, can significantly enhance the patient experience for international patients.

### 4. World-Class Expert Teams

China is home to a group of internationally renowned oncology and immunotherapy experts who have extensive clinical experience and academic achievements in hematological cancers and CAR-T therapy. Patients receive personalized treatment plans designed by leading experts, ensuring that each treatment is precisely tailored to their specific condition, maximizing effectiveness and minimizing risks.

For example, Professor Huang Xiaojun, Director of the Institute of Hematology at Peking University, is one of the world’s pioneers in haploidentical transplantation, having developed China’s haploidentical hematopoietic stem cell transplantation model. His innovative approach has increased the 3-year survival rate of leukemia patients receiving haploidentical transplants from around 20% to approximately 70%, earning him the Distinguished Service Award from the Center for International Blood and Marrow Transplant Research.

### 5. Efficient and Convenient Medical Services

China has implemented a 144-hour visa-free transit policy for citizens of 54 countries and mutual visa exemptions with 24 countries. This is a major benefit for international patients seeking treatment in China. Moreover, China’s healthcare system is known for its efficiency and convenience, especially in treating major diseases. Appointment wait times are short, and there is minimal delay in receiving treatment. A “super green channel” is also available for international patients, ensuring quick diagnosis and treatment planning. From initial consultation to online meetings with specialists, the process typically takes less than a week, with hospital admission and treatment beginning within another week.

Compared to the long waiting periods in other countries, China’s efficient medical services significantly improve treatment success rates and patient satisfaction. CAR-T therapy, in particular, is known for its high efficiency. There was an international patient who went from initial consultation to complete remission and a safe return home in less than a month—a remarkable achievement considering CAR-T is a “living” drug that must be custom-prepared using the patient’s own blood cells.

### 6. Abundant Success Stories

Many international patients who have received CAR-T therapy in China have achieved remarkable results, with their cancers being effectively controlled or even cured. These success stories not only boost confidence among patients worldwide but also attract more people to China for treatment. By sharing these stories, more patients learn about China’s advantages in CAR-T therapy and choose it as their treatment destination.

For instance, Ethan, a patient from Singapore, achieved complete remission just four weeks after CAR-T treatment and has since recovered very well. There is also the story of a Russian patient with high-risk, late-stage multiple myeloma who received efficient treatment in China at a much more reasonable cost and with a faster treatment process.

### 7. Conclusion

In conclusion, as China continues to enhance its technological capabilities in CAR-T cell therapy, more and more patients from around the world are choosing to come to China for this cutting-edge cancer treatment. With its advanced medical technology, international services, and relatively lower treatment costs, China is becoming an important destination for cancer patients seeking treatment. If you or a loved one is searching for innovative cancer treatment options, consider CAR-T therapy in China for a chance at recovery!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can contact us for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CellTherapy #CancerTreatment #Immunotherapy #HealthcareInnovation #MedicalTourism #ChinaHealthcare #CancerSurvivor #PatientStories #MedicalAdvancements #AffordableHealthcare #PersonalizedMedicine #GlobalHealth #HealthJourney #Oncology

1 month ago Lymphoma

What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China？

# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China?

Lymphoma

#CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL

In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large number of international patients seeking this cutting-edge immunotherapy. So, what types of lymphoma patients are suitable to travel to China for this advanced treatment?

## Indications: The First Choice for Relapsed or Refractory Lymphoma Patients

CAR-T treatment in China primarily targets patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Specific patient groups that are suitable include:

1. Relapsed DLBCL: Patients who did not respond to first-line treatments, such as R-CHOP, or relapsed within 12 months after treatment.

2. Follicular Lymphoma (FL): Patients with grade 1-3a FL who have relapsed or are refractory after at least two lines of treatment.

3. Mantle Cell Lymphoma (MCL): Patients whose disease remains difficult to control even after multiple treatments, including BTK inhibitors.

4. Patients whose lymphoma is resistant to traditional treatments or who experience rapid relapse after therapies such as conventional chemotherapy and targeted treatments.

5. More indications include diffuse large B-cell lymphoma (not otherwise specified), DLBCL transformed from follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, as well as grade 3b follicular lymphoma.

CAR-T therapy offers new hope to these patients by targeting the CD19 antigen on the surface of tumor cells.

## Physical Condition: Stable Health is Key

While CAR-T therapy has shown significant efficacy, the potential for serious side effects, such as cytokine release syndrome (CRS) and neurotoxicity, means that patients must be in stable health to tolerate the risks associated with treatment. Suitable patients should meet the following conditions:

– Good heart and lung function: The patient’s cardiovascular and respiratory health should be adequate to handle the stress of treatment.

– Normal liver and kidney function: Liver enzymes (such as ALT) and creatinine levels should be within normal ranges to ensure that the patient can properly eliminate toxins from the body.

– Stable immune system: Patients should not have severe infections or immunosuppressed conditions, as CAR-T therapy can further weaken the immune system, increasing the risk of infection.

Additionally, patients need to achieve a performance status score of 0-1 on the ECOG scale, indicating that they have good functional ability and can handle daily activities independently.

## Pre-Treatment Testing: Ensuring Proper Antigen Expression

CAR-T therapy targets specific antigens (such as CD19) on the surface of tumor cells, so patients’ cancer cells must express these antigens for treatment to be effective. If tests show that the tumor cells do not express the relevant antigens, CAR-T therapy will not work effectively.

## Costs and Resources: The Advantages of CAR-T in China

Compared to Western countries, CAR-T therapy in China is relatively affordable, usually costing between hundreds of thousands to one million RMB, whereas in the U.S., CAR-T treatment can cost several hundred thousand dollars. For patients with the financial ability but who find it difficult to bear the high costs of treatment in the West, China offers a significant cost advantage.

Moreover, China boasts several top-tier hospitals with established CAR-T treatment programs, such as leading cancer centers in Beijing, Shanghai, and Guangzhou. These hospitals have extensive clinical experience, offering international patients convenient access to treatment.

## Contact Us:

The Advanced Medicine in China team has a wealth of connections with doctors and hospitals, enabling us to quickly help you find the most suitable hospital and expert team for your specific needs. In China, we provide a fast-track option for CAR-T treatment.

## Conclusion

With its cost advantages, advanced medical resources, and broad indications, CAR-T therapy in China has attracted a large number of international lymphoma patients. For those who have failed traditional treatments, are in good physical condition, and have sufficient financial means, CAR-T treatment in China is an ideal choice. If you or someone close to you meets these conditions, consider coming to China for world-leading CAR-T therapy, and open the door to new hope in the fight against cancer.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!